Condition
MERS (Middle East Respiratory Syndrome)
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
5Total
P 1 (5)
Trial Status
Unknown2
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04119440Phase 1CompletedPrimary
Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS
NCT03399578Phase 1TerminatedPrimary
Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)
NCT04130594Phase 1UnknownPrimary
Study of Safety and Immunogenicity of BVRS-GamVac
NCT04128059Phase 1UnknownPrimary
Study of Safety and Immunogenicity of BVRS-GamVac-Combi
NCT03615911Phase 1CompletedPrimary
Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S
Showing all 5 trials